{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T10:28:38Z","timestamp":1768040918018,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"Commission europ\u00e9enne","doi-asserted-by":"crossref","award":["Grant Agreement number: 811729"],"award-info":[{"award-number":["Grant Agreement number: 811729"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"Commission europ\u00e9enne","doi-asserted-by":"crossref","award":["Horizon H2020"],"award-info":[{"award-number":["Horizon H2020"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40261-025-01487-y","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:11:52Z","timestamp":1759414312000},"page":"877-887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intra-arterial Injection of OTR4132, a Novel Neuroprotector in Acute Ischemic Stroke: The MaTRISS Trial"],"prefix":"10.1007","volume":"45","author":[{"given":"Xavier","family":"Barreau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Anxionnat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Heck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Sibon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Oppenheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Moniche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Sedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Chiappini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Choppin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Inizan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Barritault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Detante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"1487_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1177\/0271678X18798162","volume":"38","author":"L Shi","year":"2018","unstructured":"Shi L, Rocha M, Leak RK, et al. A new era for stroke therapy: integrating neurovascular protection with optimal reperfusion. J Cereb Blood Flow Metab. 2018;38:2073\u201391.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1487_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/svn-2021-000972","volume":"6","author":"X Guo","year":"2021","unstructured":"Guo X, Miao Z. Advances in mechanical thrombectomy for acute ischaemic stroke from large vessel occlusions. Stroke Vasc Neurol. 2021;6:649\u201357.","journal-title":"Stroke Vasc Neurol"},{"key":"1487_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2020.594613","volume":"11","author":"F Arba","year":"2021","unstructured":"Arba F, Rinaldi C, Caimano D, Vit F, Busto G, Fainardi E. Blood\u2013brain barrier disruption and hemorrhagic transformation in acute ischemic stroke. Systematic review and meta-analysis. Front Neurol. 2021;11:1\u201310.","journal-title":"Front Neurol"},{"key":"1487_CR4","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1161\/STROKEAHA.118.023927","volume":"50","author":"SI Savitz","year":"2019","unstructured":"Savitz SI, Baron JC, Fisher M, Consortium SX. Stroke treatment academic industry roundtable X: brain cytoprotection therapies in the reperfusion era. Stroke. 2019;50:1026\u201331.","journal-title":"Stroke"},{"key":"1487_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jbspin.2016.06.012","volume":"84","author":"D Barritault","year":"2017","unstructured":"Barritault D, Desgranges P, Meddahi-Pelle A, Denoix JM, Saffar JL. RGTA(R)-based matrix therapy\u2014a new branch of regenerative medicine in locomotion. Jt Bone Spine. 2017;84:283\u201392.","journal-title":"Jt Bone Spine"},{"key":"1487_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10719-016-9744-5","volume":"34","author":"D Barritault","year":"2017","unstructured":"Barritault D, Gilbert-Sirieix M, Rice KL, et al. RGTA\u00ae or regenerating agents mimic heparan sulfate in regenerative medicine: from concept to curing patients. Glycoconj J. 2017;34:325\u201338.","journal-title":"Glycoconj J"},{"key":"1487_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0141-8130(95)01074-2","volume":"18","author":"A Meddahi","year":"1996","unstructured":"Meddahi A, Lemdjabar H, Caruelle JP, Barritault D, Hornebeck W. FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. Int J Biol Macromol. 1996;18:141\u20135.","journal-title":"Int J Biol Macromol"},{"key":"1487_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.wndm.2020.100180","volume":"28","author":"D Barritault","year":"2020","unstructured":"Barritault D. Overview of 10 years of practice with CACIPLIQ20\u00ae matrix therapy as a healing agent for hard to heal wounds: efficacy, cost-effectiveness and future perspectives. Wound Med. 2020;28:100180.","journal-title":"Wound Med"},{"key":"1487_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.biomaterials.2010.09.043","volume":"32","author":"Y Ikeda","year":"2011","unstructured":"Ikeda Y, Charef S, Ouidja MO, et al. Synthesis and biological activities of a library of glycosaminoglycans mimetic oligosaccharides. Biomaterials. 2011;32:769\u201376.","journal-title":"Biomaterials"},{"issue":"8","key":"1487_CR10","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.7150\/thno.28252","volume":"2018","author":"Y Khelif","year":"2018","unstructured":"Khelif Y, Toutain J, Quittet MS, et al. A heparan sulfate-based matrix therapy reduces brain damage and enhances functional recovery following stroke. Theranostics. 2018;2018(8):5814\u201327.","journal-title":"Theranostics"},{"key":"1487_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10719-022-10047-x","volume":"39","author":"PM Pereira","year":"2022","unstructured":"Pereira PM, Papy-Garcia D, Barritault D, Chiappini F, Jackisch R, Schimchowitsch S, et al. Protective effects of a synthetic glycosaminoglycan mimetic (OTR4132) in a rat immunotoxic lesion model of septohippocampal cholinergic degeneration. Glycoconj J. 2022;39:107\u201330.","journal-title":"Glycoconj J"},{"key":"1487_CR12","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1161\/STROKEAHA.115.010049","volume":"46","author":"R Von Kummer","year":"2015","unstructured":"Von Kummer R, Broderick JP, Campbell BC, et al. The Heidelberg Bleeding Classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke. 2015;46:2981\u20136.","journal-title":"Stroke"},{"key":"1487_CR13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/STROKEAHA.116.016368","volume":"48","author":"Y Hao","year":"2017","unstructured":"Hao Y, Yang D, Wang H, et al. Predictors for symptomatic intracranial hemorrhage after endovascular treatment of acute ischemic stroke. Stroke. 2017;48:1203\u20139.","journal-title":"Stroke"},{"key":"1487_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.122999","volume":"460","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Katano T, Numao S, et al. Clinical significance of intracranial hemorrhage after thrombectomy detected solely by magnetic resonance imaging and not by computed tomography. J Neurol Sci. 2024;460:122999.","journal-title":"J Neurol Sci"},{"key":"1487_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.582605","volume":"11","author":"N Matei","year":"2021","unstructured":"Matei N, Camara J, Zhang JH. The next step in the treatment of stroke. Front Neurol. 2021;11:582605.","journal-title":"Front Neurol"},{"key":"1487_CR16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","volume":"14","author":"MD Hill","year":"2020","unstructured":"Hill MD, Goyal M, Menon BK, ESCAPE-NA1 Investigators, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020;14:878\u201387.","journal-title":"Lancet"},{"key":"1487_CR17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaneurol.2023.1871","volume":"80","author":"A Wang","year":"2023","unstructured":"Wang A, Jia B, Zhang X, et al. Efficacy and safety of butylphthalide in patients with acute ischemic stroke: a randomized clinical trial. JAMA Neurol. 2023;80:851\u20139.","journal-title":"JAMA Neurol"},{"key":"1487_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biology12030407","volume":"12","author":"SL Lindsay","year":"2023","unstructured":"Lindsay SL, Sherrard Smith R, Yates EA, et al. Validation of recombinant heparan sulphate reagents for CNS repair. Biology. 2023;12:407.","journal-title":"Biology"},{"key":"1487_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ph10040078","volume":"10","author":"S Mohamed","year":"2017","unstructured":"Mohamed S, Coombe DR. Heparin mimetics: their therapeutic potential. Pharmaceuticals (Basel). 2017;10:78.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1487_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s40883-017-0037-8","volume":"3","author":"DM Gardiner","year":"2017","unstructured":"Gardiner DM. Regulation of regeneration by heparan sulfate proteoglycans in the extracellular matrix. Regen Eng Transl Med. 2017;3:192\u20138.","journal-title":"Regen Eng Transl Med"},{"key":"1487_CR21","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/jbm.a.31385","volume":"83","author":"S Charef","year":"2007","unstructured":"Charef S, Petit E, Barritault D, Courty J, Caruelle JP. Effects on coagulation of a synthetic heparan mimetic given intraperitoneally or orally. J Biomed Mater Res A. 2007;83:1024\u201331.","journal-title":"J Biomed Mater Res A"},{"key":"1487_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/WCO.0b013e3282f36cb6","volume":"21","author":"SC Cramer","year":"2008","unstructured":"Cramer SC, Riley JD. Neuroplasticity and brain repair after stroke. Curr Opin Neurol. 2008;21:76\u201382.","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"1487_CR23","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1111\/j.1582-4934.2012.01575.x","volume":"16","author":"M Guti\u00e9rrez-Fern\u00e1ndez","year":"2012","unstructured":"Guti\u00e9rrez-Fern\u00e1ndez M, Fuentes B, Rodr\u00edguez-Frutos B, Ramos-Cejudo J, Vallejo-Cremades MT, D\u00edez-Tejedor E. Trophic factors and cell therapy to stimulate brain repair after ischaemic stroke. J Cell Mol Med. 2012;16(10):2280\u201390. https:\/\/doi.org\/10.1111\/j.1582-4934.2012.01575.x.","journal-title":"J Cell Mol Med"},{"key":"1487_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00790","volume":"13","author":"J Houlton","year":"2019","unstructured":"Houlton J, Abumaria N, Hinkley SFR, Clarkson AN. Therapeutic potential of neurotrophins for repair after brain injury: a helping hand from biomaterials. Front Neurosci. 2019;13:790. https:\/\/doi.org\/10.3389\/fnins.2019.00790.","journal-title":"Front Neurosci"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01487-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01487-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01487-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:57:34Z","timestamp":1760774254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01487-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1487"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01487-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Denis Barritault is co-inventor and co-owner in the patents describing RGTA\u00ae technology and applications. He is the founder, president, and shareholder of the company OTR3, which manufactures and commercializes CACIPLIQ20\u00ae. Frederic Sedel, Martin Inizan, Franck Chiappini, and Agnes Choppin are employees and shareholders of OTR3 and are co-inventors of patents describing OTR4132-MD technology and applications. Charlotte Rosso, Catherine Oppenheim, and Francisco Moniche received fees for their work as members of the independent data safety monitoring board. Other authors declare no conflicts of interest in relation with this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was approved by the ethics committee (Comit\u00e9 de protection des personnes Ile de France 5) under the reference 21.01365.000016 and by the French regulatory authority (Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9) under the reference DMCDIV\/FLOW\/AE\/2018-A03117-48-B\/MS2. The study was performed in accordance with the standards of ethics outlined in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent followed an emergency procedure with three different possibilities: (1) direct patient informed consent when the patient was conscious and able to provide its consent, (2) legal representative if the patient was not able to provide their consent, and (3) an independent physician (not investigator in the study) when the patient was not able to provide their consent and when there was no legal representative available. In cases (2) and (3), patient\u2019s written informed consent was obtained afterwards, once the patient recovered sufficiently, in order to continue the study follow-up and to authorize the use of study data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Study data are available on request to the sponsor OTR3.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"All authors contributed to this work and provided feedback on the drafting of the manuscript. Olivier Detante, Frederic Sedel, Martin Inizan, and Denis Barritault were involved in the design of the clinical trial. Olivier Detante, Xavier Barreau, Ren\u00e9 Anxionnat, Olivier Heck, and Igor Sibon were investigators in the study and participated in the collection and analysis of the data. Charlotte Rosso, Catherine Oppenheim, and Francisco Moniche were members of the data safety monitoring board and were involved in data interpretation, dose escalation, methodological aspects, revising the manuscript for important intellectual content, and final approval of the version to be published. Franck Chiappini and Agn\u00e8s Choppin were involved in the preclinical phases, data analysis and representation, funding, and submission to regulatory authorities. All authors read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contributions"}}]}}